智通财经网·2026-01-27 10:16Group 1 - The core point of the article is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., has had its HRS-5346 tablets included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) [1] - Elevated lipoprotein(a) [Lp(a)] levels are a common genetic lipid disorder, with prevalence rates in Chinese adults exceeding 30 mg/dL and 50 mg/dL at 18.67% and 8.41%, respectively [1] - High Lp(a) is confirmed as an independent risk factor for atherosclerotic cardiovascular diseases, including coronary heart disease, ischemic stroke, peripheral vascular disease, and calcific aortic stenosis [1] - Targeting Lp(a) with lipid-lowering therapies represents a significant breakthrough direction in the prevention and treatment of cardiovascular diseases [1] - HRS-5346 is an oral small molecule inhibitor of Lp(a), and currently, there are no similar products approved for sale domestically or internationally [1] - The cumulative R&D investment for HRS-5346 is approximately 76.3 million yuan (unaudited) [1] Group 2 - The NMPA's breakthrough therapy program aims to prioritize resource allocation for drugs included in the program, enhancing communication and guidance to promote drug development [2] - Drug development is influenced by various factors, including technology, approval processes, and policies, leading to uncertainties in review policies and future market competition [2]